Safety and tolerability of insulin aspart biosimilar SAR341402 versus originator insulin aspart (NovoLog®) when used in insulin pumps in adults with type 1 diabetes: A randomized, open-label clinical trial.
2019
Background: The aim was to assess the safety and tolerability of the insulin aspart biosimilar/follow-on product SAR341402 (100 U/mL solution; SAR-Asp) and originator insulin aspart (100 U/mL; NN-A...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
18
References
3
Citations
NaN
KQI